Baxter International Inc (BAX) : Lvm Capital Management Ltdmi reduced its stake in Baxter International Inc by 16.42% during the most recent quarter end. The investment management company now holds a total of 8,525 shares of Baxter International Inc which is valued at $357,539 after selling 1,675 shares in Baxter International Inc according to a report filed by the company on Apr 4, 2016 with the SEC.Baxter International Inc makes up approximately 0.11% of Lvm Capital Management Ltdmi’s portfolio.
Other Hedge Funds, Including , Beacon Financial Group boosted its stake in BAX in the latest quarter, The investment management firm added 5,640 additional shares and now holds a total of 13,911 shares of Baxter International Inc which is valued at $579,950. Baxter International Inc makes up approx 0.13% of Beacon Financial Group’s portfolio.
On the company’s financial health, Baxter International Inc reported $0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.32. The company had revenue of $2603.00 million for the quarter, compared to analysts expectations of $2544.60 million. The company’s revenue was down -6.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.34 EPS.
Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 40 from a previous price target of $37 .
Baxter International Inc opened for trading at $41.96 and hit $42.225 on the upside on Monday, eventually ending the session at $41.94, with a gain of 0.24% or 0.1 points. The heightened volatility saw the trading volume jump to 35,29,950 shares. Company has a market cap of $22,978 M.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.